Review discusses how Salmonella exploits immune responses and metabolites for gut colonization, highlighting potential therapies.
Salmonella enterica serovar Typhimurium (STm) is a leading cause of diarrheal disease and efficiently colonizes the gut lumen despite microbiota-mediated colonization resistance. Emerging evidence indicates that STm does not simply evade or overcome these barriers, but instead exploits host immune responses and microbiota-derived metabolic activities to create a permissive intestinal niche. In this review, we discuss recent advances in our understanding of STm gut colonization, with a focus on how host antimicrobial factors and microbiota-derived metabolites are repurposed to promote pathogen growth, motility, and invasion. We highlight findings showing that the antimicrobial lectin RegIIIβ, together with microbiota-dependent metabolites such as fatty acid-derived cues and polyamines, can unexpectedly facilitate STm colonization. Together, these studies support a model in which host defense programs and microbial metabolism are redirected to promote pathogen fitness, revealing potential therapeutic opportunities for controlling enteric infections.
No takes yet. Share an insight, caveat, or question.
Miki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: